Robert J Bielski

Summary

Publications

  1. ncbi A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder
    Robert J Bielski
    Summit Research Network, Okemos, MI 48864, USA
    J Clin Psychiatry 65:1190-6. 2004
  2. ncbi A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder
    Robert J Bielski
    Summit Research Network, 4084 Okemos Road Suite C, Okemos, MI 48864, USA
    Ann Clin Psychiatry 17:65-9. 2005
  3. ncbi Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study
    Robert J Bielski
    Summit Research Network, Inc, Okemos, Mich 48864, USA
    J Clin Psychiatry 69:571-7. 2008
  4. ncbi Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003
  5. ncbi Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005

Detail Information

Publications5

  1. ncbi A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder
    Robert J Bielski
    Summit Research Network, Okemos, MI 48864, USA
    J Clin Psychiatry 65:1190-6. 2004
    ..Venlafaxine is a non-selective SRI that also inhibits noradrenergic re-uptake. This study compared escitalopram and venlafaxine extended release (XR) in depressed outpatients at the highest doses recommended in the United States...
  2. ncbi A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder
    Robert J Bielski
    Summit Research Network, 4084 Okemos Road Suite C, Okemos, MI 48864, USA
    Ann Clin Psychiatry 17:65-9. 2005
    ..This study compared the efficacy and tolerability of escitalopram, a newer SSRI, with paroxetine in the treatment of generalized anxiety disorder (GAD)...
  3. ncbi Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study
    Robert J Bielski
    Summit Research Network, Inc, Okemos, Mich 48864, USA
    J Clin Psychiatry 69:571-7. 2008
    ..To evaluate the efficacy and tolerability of extended-release gepirone (gepirone-ER), a 5-HT(1A) agonist, versus placebo in the treatment of adult outpatients with major depressive disorder (MDD)...
  4. ncbi Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003
    ..Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder...
  5. ncbi Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005
    ..Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord...